Plain-English translation of NCT07403604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called diazoxide can help reduce fat accumulation in the liver. The study focuses on people whose bodies don't respond properly to insulin (insulin resistance) and who have developed fatty liver disease. Researchers believe that lowering insulin levels with this medication might help prevent the liver from making too much fat.
Many people with obesity and prediabetes develop fatty liver disease, but doctors don't fully understand how insulin resistance causes this problem. This trial aims to test whether lowering insulin levels with this medication could be a new way to reduce liver fat and prevent serious liver complications.
You likely qualify if…
You likely don't qualify if…
You would participate in two separate one-week study periods, spaced 4 to 12 weeks apart. During each period, you'll take either the medication or a placebo twice daily for seven days, drink specially labeled water to help researchers measure liver fat production, and come in for blood draws and saliva samples at the beginning and end of each week. Most participants (80%) will take the medication during the second period, while a smaller group will receive placebo both times as a control.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States